Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia
This study is a single-arm, open label, phase I clinical trial to evaluate the safety and feasibility of CD19CAR-T in treatment of relapsed / refractory acute lymphoblasic leukemia.
Relapsed Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia
COMBINATION_PRODUCT: CD19 CART
recovery rate of patients being treated with CD19CAR-T, the recovery rate of patients consists of complete recovery rate and partial recovery rate of patients being treated with CD19 CAR-T, 6 months
This study is a single-arm, open label, phase I clinical trial to evaluate the safety and feasibility of CD19CAR-T in treatment of relapsed / refractory acute lymphoblasic leukemia.